FTSE 100 movers: Sky lifted by broker comments
14th Jan 2014 15:07
UBS upgraded BSkyB to 'buy' this morning, giving the stock a decent lift as it said that competitive concerns have been priced in and growth opportunities are now being overlooked at the broadband and pay-TV group. It also sees M&A upside in the stock, speculating about a possible merger by Fox to c
Read moreLondon midday: Stocks lower but losses trimmed as inflation eases
14th Jan 2014 11:20
- CPI inflation falls to BoE target - US earnings season in focus - UBS sees merger opportunities at BSkyB - Ashmore reports fall in AuM techMARK 2,800.75 -0.09% FTSE 100 6,740.89 -0.24% FTSE 250 16,152.84 -0.63% Nervousness ahead of the US earnings season and a disappointing update from fund mana
Read moreLondon open: Markets pull back from 10-week high, Ashmore drops
14th Jan 2014 08:35
- Ashmore reports fall in AuM, drags peers lower - Lockhart quashes stimulus optimism - FTSE 100 pulls back from 10-week high techMARK 2,798.85 -0.16% FTSE 100 6,723.86 -0.49% FTSE 250 16,144.85 -0.68% A disappointing set of results from Ashmore and a host of other stocks on the FTSE 350 dampened
Read moreAstraZeneca foresees sooner-than-expected return to growth
14th Jan 2014 07:09
Biopharmaceutical giant AstraZeneca has said it expects to return to growth sooner than analysts currently predict. Chief Executive Officer Pascal Soriot said that the company has made good progress in accelerating and replenishing its portfolio in its three core therapeutic areas of oncology, card
Read moreLondon pre-open: FTSE to slump at opening bell
14th Jan 2014 07:02
- Drop of 37 points expected early on - S&P 500 registers worst performance in two months - Focus on UK inflation City sources predict the FTSE 100 will open 37 points below yesterday's close of 6,757.15, tracking declines seen in the US overnight, which saw the S&P 500 register its poorest perform
Read moreLondon pre-open: FTSE to begin week with a slow start
13th Jan 2014 07:29
City sources predict the FTSE 100 will open 13 points higher than Friday's close of 6,739.94, as investors weigh up last week's US jobs data and a mixed performance by Asia stocks overnight. According to Craig Erlam from Alpari, the fact stocks are set to move higher early on "suggests that we're
Read moreAstraZeneca's diabetes drug Farxiga approved by FDA
13th Jan 2014 07:08
AstraZeneca's diabetes drug Farxiga has been approved by the US Food and Drug Administration. The drug, which AstraZeneca developed with Bristol-Myers Squibb Company, is a once-daily oral treatment to improve glycaemic control in adults with type 2 diabetes mellitus. The drug can be taken with or
Read moreAstraZeneca gets US FDA approval for Farxiga diabetes drug
9th Jan 2014 08:00
Drug-maker AstraZeneca was given a boost as a diabetes treatment was given the green light by the US regulator. Broker JPMorgan Cazenove has forecast a $600m peak in-market potential in the US for the treatment, though admitted this could prove conservative, with Morningstar analyst Damien Conover
Read moreWednesday newspaper round-up: AstraZeneca, SSE, IMF...
8th Jan 2014 07:19
AstraZeneca has struck a deal with a fast-growing UK biotech company to develop treatments that use the body's immune system to fight cancer. The partnership with privately owned Immunocore highlights intensifying interest from big pharmaceutical groups in what many experts consider the most promisi
Read moreLondon open: Retailers give markets a boost after Boxing Day sales
27th Dec 2013 09:22
- IPF plummets after news of Polish fine - Shoppers hit the streets for Boxing Day sales - US jobless claims drop by 42,000 techMARK 2,776.01 +0.26% FTSE 100 6,724.97 +0.46% FTSE 250 15,801.26 +0.12% UK markets headed higher on Friday morning, reopening strongly after the Christmas holidays, as in
Read moreAstraZeneca reduces Crestor royalty rates with Shionogi
27th Dec 2013 08:27
Pharmaceuticals group AstraZeneca has settled arbitration proceedings with Japanese group Shionogi & Co over the calculation of royalties related to its cholesterol treatment Crestor. As part of the agreement, payments from Astra to Shionogi have been adjusted to reduce the royalty rate in 2014-20
Read moreFriday tips round-up: AstraZeneca, Vodafone
20th Dec 2013 14:24
New AstraZeneca Chief Pascal Soriot made another decisive move on Thursday to return the company quickly back to growth, by acquiring the 50 per cent he did not already own of the firm's global diabetes joint-venture with Brystol Myers Squibb for 4.3bn dollars. The disease, which now afflicts 350m p
Read moreLondon close: Stocks surge to two-and-a-half-week high after Fed taper
19th Dec 2013 16:31
- FTSE 100 at highest since December 2nd after Fed taper - Fed scales back stimulus, gives guidance on rates - Carnival jumps late on after FY results - Pharmaceutical and life insurance stocks rise techMARK 2,735.02 +1.40% FTSE 100 6,584.70 +1.43% FTSE 250 15,589.95 +1.45% UK stocks surged to a t
Read moreFTSE 100 movers: Carnival buoyed by Q4 results, drugmakers higher
19th Dec 2013 14:47
Cruise operator Carnival surged into the top spot on the FTSE 100 risers list on Thursday after reporting a smaller-than-expected decline in net revenue yields in the fourth quarter. Net revenue yields in constant dollars fell by 2.1 per cent year-on-year, better than the company's guidance given in
Read moreAberdeen Deputy CEO trousers 5.4m pounds as shares 10-year high
19th Dec 2013 14:39
It was revealed that Aberdeen Asset Management's Deputy Chief Executive Officer (CEO) Andrew Laing sold 2.6m pounds in shares earlier this week as well as selling 2.7m pounds-worth of new shares awarded in his long-term bonus plan. Aberdeen shares recently hit heights not seen since 2001. Down th
Read more